Whole cell cancer vaccines are currently under clinical evaluation. Their immunogenicity may depend on the mode of death of the vaccine cells prior to uptake by professional antigen-presenting cells and crosspriming of T cells. Destruction of tumor in vivo by genetic prodrug activation therapy leads to a marked local and systemic immune response, local T-cell infiltration and the establishment of T-cell memory. We postulated that this immunostimulation may be due to induction of danger signals and the inherent immunogenicity of products of HSVtk/ganciclovir kill. Using established models of murine prostate cancer, we have evaluated the efficacy of anti-tumor vaccines comprising irradiated allogeneic or autologous whole cells expressing HSVtK, which are first killed in vitro by prodrug activation using ganciclovir. HSVtk/ganciclovir-induced cell kill was through the induction of apoptosis. The vaccine was found to be effective in both models and superior to traditional irradiated whole tumor cells even after single doses. Protection against tumor challenge was associated with marked proliferative and Th1 cytokine responses. This approach would be applicable clinically in terms of ease of vaccine production, safety, storage and avoidance of potential toxicities of in vivo gene transfer.
T he outlook for men with hormone refractory prostate cancer (CaP) is bleak, which justifies the development of novel therapeutic strategies such as immunomodulation to control disease progression. [1] [2] [3] [4] [5] The attractions of using whole tumor cells or their lysates as vaccines include the presentation of a whole (and not necessarily defined) repertoire of tumor-associated antigens (TAA). Vaccines using allogeneic cell material may be required when tissue procurement and generation of autologous cell lines (as in the case of prostate cancer) is difficult. Allogeneic cell vaccines provide a similar repertoire of antigens as the host tumor, do not require HLA matching and have powerful adjuvant effects based on the concept of alloaggression in which T cells react directly against the allo-MHC antigens. 6 The antitumor effects of both autologous and allogeneic cell vaccines may be further enhanced by modifying the cells to express cytokines such as GMCSF, 7 costimulatory molecules, 8 heat shock proteins 9 or suicide genes, which induce marked local, systemic and memory immune response. 10, 11 Killed tumor cells have been shown to be the source of TAA for processing and presentation by dendritic cells (DCs). 12, 13 Their immunostimulatory potential may depend on the mode (apoptosis versus necrosis) of cell death but may be limited by expression of immunosuppressive factors in the tumor microenvironment. 14 We postulated that the products of HSVtkexpressing tumor cells killed by exposure to ganciclovir in vitro would be immunogenic as intradermal vaccines animals. In vitro killing in this way would allow the efficient, evaluable and reproducible induction of immunogenic apoptotic or necrotic cell death, exploit any adjuvant effects of the transgene and allow crosspriming of tumor antigens in the dermis. Using established models of murine prostate cancer, we assessed the antitumor activity of autologous and allogeneic tumor cells modified to express the suicide gene herpes simplex viral thymidine kinase (HSVtK) and killed in vitro by prodrug activation using ganciclovir prior to immunization. A cancer vaccine designed in this way would be suitable for clinical application as tumor from individual patients would not be required, would avoid the potential toxicities of in vivo gene transfer and would have added advantages of ease of large scale production, storage, administration and safety.
(ECACC) and was cultured in Dulbecco modified Eagle's minimal essential medium (DMEM, Sigma, Poole, UK), 10% heat inactivated fetal calf serum (Sigma), 2 mm glutamine (Sigma), penicillin 100 mg/ml (Life Technologies, Paisley, UK) and streptomycin 100 mg/ml (Life Technologies) in 5% CO 2 . The PAIII rat prostate cancer cell line was kindly provided by Dr Morris Pollard (Lobund Laboratory, Indiana, USA) and was cultured in DMEM (Sigma), 10% heat inactivated fetal calf serum (Sigma), 2 mm glutamine (Sigma), penicillin 100 mg/ml, streptomycin 100 mg/ml, in 5% CO 2 . The cells were passaged with 0.05% trypsin and 0.02% EDTA (Sigma) and were free from mycoplasma as assessed by the gene probe method (Gen-Probe, San Diego, CA, USA).
Immunohistochemistry
Cell lines were trypsinized, washed in Hank's balanced salt solution (HBSS) and resuspended in 0.9% saline at 1 Â 10 5 ml. A volume of 200 ml of this suspension was cytospun, air dried overnight and fixed in acetone for 10 minutes. Staining was performed using the DAKO EnVision þ System, Peroxidase (DAB) (DAKO, Carpinteria, CA) Kit. Blocking was performed using 0.03% hydrogen peroxide (DAKO) for 5 minutes. Slides were rinsed with TBST (0.1% (v/v) Tween 20) and overlaid with anti-HSVtK antibody (MTM Laboratories, 1 in 100 dilution) diluted in 0.05 M Tris-HCl buffer, pH 7.2, containing 1% bovine serum albumin (Sigma) for 30 minutes. After washing with TBST, Labelled Polymer (DAKO) was added and incubated for 30 minutes followed by a further wash in TBST. For signal detection, the slides were incubated with 3,3 0 -diaminobenzidine chromogen solution with suffered substrate (DAKO) for 10 minutes. Slides were rinsed in tap water and counterstained with hematoxylin.
Vaccine preparation
The gene encoding HSVtk was cloned into pBabeNeo and this construct was transfected into the AM12 retroviral packaging cell line, as described previously. This packaging cell line was kindly provided by Dr R Vile (Mayo Clinic, Rochester, MN). Cells were transfected as previously described. 10 Viral supernatant harvested from these cells was used to transfect the rat prostate tumor lines in the presence of 4 mg/ml polybrene. Clones were grown in neomycin (G418) (150 mg/ml for MLL and 500 mg/ml for PAIII) and then tested for their sensitivity to killing by ganciclovir (Cymevene, Roche) at a range of concentrations compared to wild-type cells, previously shown. 10 HSVtK transfectants of MLL and PAIII were referred to as MtK and PtK, respectively.
Prophylactic vaccination experiments
Pathogen-free 12-week-old male Lobund-Wistar rats (Lobs) were obtained from Harlan (USA). All procedures were carried out under mild anesthesia and in accordance with the UK Home Office and ethical guidelines. MtK and PtK cells were plated out and cultured in either medium alone or medium containing 5 mg/ml ganciclovir. After 3 days culture the cells were harvested. The attached cells were detached in the routine manner using trypsin and pooled with any floating cells. For the comparator traditional whole cell vaccine, cells were resuspended at a concentration of 5 Â 10 6 cells in 200 ml of PBS, placed in a sterile container and irradiated 50 Gy. For the gene modified vaccine, the same number of cells were exposed to 5 mg/ml ganciclovir for 72 hours, all cellular material precipitated by centrifugation and irradiated 50 Gy. Animals were vaccinated in the left thigh at day 0 with either PBS for control groups or irradiated whole cells. All vaccination groups received 5 Â 10 6 cells in 200 ml PBS. The tumor cells were prepared for tumor challenge by detachment with trypsin, washed three times in PBS and resuspended at the specified density in PBS. Prostatic tumors were induced ectopically by the injection of 1 Â 10 6 PAIII cells in 200 ml PBS subcutaneously into the shaven thigh of each Lobund-Wistar rat, as optimized previously 1 to measure perpendicular diameters. The groups were PBS only, MtK, PtK, MtK treated with ganciclovir and PtK treated with ganciclovir. On day 7 all animals were challenged with 1 Â 10 6 PAIII cells in 200 ml PBS subcutaneously into the right thigh. tumor size in mm 3 was determined by measuring the largest and smallest diameter with microcalipers, and calculated as length Â (width 
Immune responses
Spleens were taken from rats 7 days post vaccination, five rats in each group. The spleens were passed through 100 mm filters to obtain a single-cell suspension in DMEM and then red cells were lysed with Purescript RBC lysis solution (Gentra Systems, Minneapolis, MN). The cells were washed and resuspended in DMEM supplemented with FCS, glutamine, penicillin and streptomycin as before. Cells at 1 Â 10 6 /ml were cultured with irradiated (50 Gy) tumor cells at ratios from 20 to 360 lymphocytes to one tumor cell in triplicate in 96-well plates, plates were set up in duplicate. After 48 hours, supernatants were collected from one set of plates and tested for cytokines IFNg and IL10 using ELISA kits from R and D systems (Minneapolis, MN), following the manufacturer's instructions. Proliferation was measured on day 5 following 18 hours of pulsing with 1 mCithymidine per well. 15 Mean values of triplicates were expressed as counts per minute (c.p.m.).
Results

In vitro characteristics of the HSVtK-expressing cell lines
Expression of HSVtK in the transfected cell lines PtK and MtK was confirmed using immunohistochemistry and is shown in Figure 1 . No morphological alterations or differences in cell growth were observed in the transfected cell lines when compared to their parental cell lines. After transfection, HSVtK-expressing cells were selected by the Immunotherapy of murine CaP using whole tumor cells H Pandha et al addition of G418 to culture medium. Subsequently, all cell culture medium used contained G418 at the same concentration. Sensitivity of HSVtK-transfected and nontransfected PAIII and MLL cells to ganciclovir and evidence of an in vitro bystander effect has been previously published by our group. 10 MLL was found to be more sensitive to ganciclovir, but there was incomplete cell kill even at maximum doses of ganciclovir. The predominant mode of cell death as a result of exposure to ganciclovir was by apoptosis, also shown previously by our group. 10 There was no evidence of induction of heat shock protein (HSP)70 by Western blot in any of the cell lines, before or after ganciclovir exposure (data not shown).
HSVtK/ganciclovir-killed tumor cells used as vaccines: immunity against autologous parental tumor cells
Previous studies have shown that syngeneic and allogeneic whole cell vaccines and tumor lystes are effective inducing cellular immunity and, in animal models, resisting parental tumor challenge. In our recent study, whole cell vaccination was also shown to be effective after heating and the induction of HSP70. 16 As we had postulated that the HSVtK/ganciclovir kill would enhance immunogenicity of our vaccines, we compared the effect of vaccines comprising syngeneic (PAIII) and allogeneic (MLL) cells, their HSVtK-transfected counterparts (PtK and MtK respectively) as well as ganciclovir-killed PtK and MtK. Groups of five Lobund-Wistar rats were vaccinated on day 0, and on day 7 were challenged with 1 Â 10 6 parental PAIII cells subcutaneously into the right flank. Animals were killed when the largest tumor diameter reached 30 mm. All experiments were repeated at least twice.
Autologous. Following autologous vaccination with PAIII, PtK, PtK/ganciclovir-killed cells and subsequent tumor challenge, the rate of tumor growth was slower in the group receiving HSVtK-ganciclovir-killed vaccine after 55 days compared to irradiated unmodified PAIII cells and saline control groups (Fig 2) . This was statistically significant by day 33, P ¼ .05. Both were superior to saline-injected controls. Five rats were evaluated in each treatment and control group. This was further reflected in a significant survival benefit for PtK/ ganciclovir-treated animals compared to those treated with nonmodified irradiated autologous PAIII cells, P ¼ .04 (Fig 3) . (Fig 4) , P ¼ .05 by day 18. This was further reflected in an overall survival benefit for the MtK/ganciclovir-killed vaccine group over its irradiated whole cell (MLL) comparator at the same time point (Fig 5) , Po.02 by day 30. Both vaccines were superior to saline controls.
Allogeneic vaccination.
Rechallenge of protected animals. From both the previous experiments, animals tumor free at 60 days were challenged once again with the same dose of parental tumor. A new control group of five rats received the same inoculum of parental PAIII cell subcutaneously. Although the numbers from each group was too small for statistical analysis, it was clear that rats resisting initial tumor challenge irrelevant of type of vaccine used had PAIII PtK MLL MtK 
Immunological responses to vaccination
Proliferation to parental tumor cells. Proliferative responses to vaccine have been demonstrated in a number of cellular therapy models and now constitute a clinical ''readout'' in human trials. A 5-day proliferation assay using thymidine incorporation was used to assess the reactivity of splenocytes taken from treated or PBS control rats to irradiated parental tumor. We found that maximum proliferation was seen at a ratio of 1:40 stimulators to responders. The highest proliferation was seen in the MLL model in response to HSVtK/ganciclovir killing. In the PAIII models, there was a markedly higher proliferative response in rats receiving the PtK/ganciclovir-killed vaccine compared to PtK or parental cells and PBS controls (Fig 6) .
Cytokine expression. An assessment of cytokine expression by splenocytes cocultured with irradiated parental cell lines was made using an ELISA assay. In both autologous and allogeneic models, the predominant response was of a Th-1 variety with significantly more interferon-g production in rats treated with HSVtK-killed vaccine than PAIII or PBS controls. Interestingly, although very little IL-10 was produced, this was by the group receiving PAIII vaccine. Representative ELISA data are shown in Figure 7a and b.
Discussion
The antitumor efficacy of whole cell cancer vaccines has been enhanced by specific modifications such as the use of alloantigens, induction of apoptosis or necrosis, the expression of stress proteins by heating, 16 or by transfection with immunostimulatory cytokine genes. 17 HSVtK phosphorylates ganciclovir to produce a cytotoxic triphosphorylated metabolite . The cell destruction achieved by this system and the associated bystander effect has been extensively reported 18, 19 and is thought to be mediated by two mechanisms: (i) toxic metabolites are able to traverse to and kill neighboring cells, and (ii) cell killing in vivo initiating an inflammatory immune response capable of killing local and distant untransfected cells. 20, 21 However, the precise mechanisms of ganciclovir activation, cell kill and induction of apoptosis are not fully understood. 
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Triphosphorylated ganciclovir is genotoxic and a potent recombogenic and chromosomal-break-inducing agent. Ganciclovir-associated apoptosis is a replication-dependent process associated with bcl-2 decline, amplified by caspase 9-driven cleavage of bcl-2. 22 We previously found that rat prostate tumor cells killed by HSVtK/ganciclovir died predominantly by apoptosis. 10 We postulated that killing HSVtK-expressing CaP cells ex vivo would enhance their immunogenicity through the induction of apoptotic death and specific caspase expression, crosspriming to T cells through uptake of apoptotic material by DCs after injection into the dermis, plus the adjuvant effects of ganciclovir conversion metabolites.
We found that vaccine produced this way was superior to equivalent nontransfected irradiated whole cell vaccine. We had previously defined the sensitivity of rat CaP lines to this suicide gene system. The two rat prostate cell lines MLL and PAIII express MHC class I molecules, are immunogenic and have been used as cancer vaccine models previously by our group. 23 The limitations of this model include the lack of PSA secretion by both lines and their pattern of metastasis. Both cell lines were easily transfected with the HSVtK gene as shown by immunocytochemistry. Expression of HSVtK has been associated increased sensitivity to ganciclovir in both cell lines, particularly with the MtK cells. 10 In contrast to other models using the same suicide gene system, even at high levels of prodrug, there was incomplete cell kill of both cell lines, and evidence of an in vitro bystander effect, more pronounced with PtK than MtK. 10 Although screening with Western blot was negative for inducible HSP70 (data not shown), it is possible that other HSPs were induced. Tumor-derived heat shock HSPs such as glycoprotein 96 (GP96) HSP90, HSP70 and calreticulin are chaperone proteins, which may supply both antigens and danger signal to the immune system, [24] [25] [26] and when used as vaccines can induce protective immunity against their tumors of origin. 27, 28 Cell kill using HSVtK/ ganciclovir has been associated with both apoptotic and nonapoptotic death according to the model evaluated. For cells undergoing necrotic cell death, the increased immunogenicity of the dying cells has been directly associated with increased expression of HSP70 and decreased expression of the immunosuppressive cytokine IL-10. 29 HSVtK/ganciclovir kill has also been associated with upregulation of costimulatory molecules such as B7.1 and adhesion molecules such as ICAM. 30 Early reports suggested that phagocytosed apoptotic cells could exclusively crosspresent antigens to cytotoxic T lymphocytes (CTL). 31 However, further studies have shown that tolerance may be induced in dendritic cells that have captured apoptotic cells. 32 It is important to note that agents that induce apoptosis of nonsynchronized tumor cells often yield a population containing a mixture of viable, apoptotic and necrotic cells in various populations. In our model, there was incomplete kill using ganciclovir so this was possible. It was necessary to transfect cells with HSVtK and then kill with ganciclovir rather than expose nontransfected cells with large doses of ganciclovir for several reasons. Firstly, increasing the doses of ganciclovir several fold did not result in any improvement in cell kill efficiency (data not shown). Secondly, we wished to exploit any potential increased innate immunogenicity from the stable integration of the transgene and any viral elements. Finally, the increased sensitivity of the transfected cell lines to low doses of ganciclovir would be cost effective. Our in vivo models showed that, both in the autologous and the allogeneic context, the use of HSVtK/ganciclovir-killed vaccine resulted in slower tumor growth and extended survival. 
This was reproducibly observed after only single vaccination and without the use of any adjuvant. The magnitude of the protection effect was similar with both types of antigen suggesting similar levels of immune activation and crosspresentation of antigen. There was evidence of the induction of immunological memory from observations that animals surviving initial syngeneic tumor challenge were then completely resistant to further tumor challenge (data not shown). The enhanced immunogenicity of the vaccines was confirmed by the proliferative responses, higher after allogeneic vaccination, seen in splenocytes from vaccinated animals compared to nonvaccinated controls. This was further corroborated by the observed T helper1 cytokine response, normally associated with the activation of macrophages and induction of cytotoxic T cells, with increased levels of interferon gamma in vaccinated versus saline control animals. The marked reduction in IL-10 secretion was associated with killed vaccine and was observed with both types of cell vaccine. We believe that the immunogenicity of HSVtK/ganciclovir kill was not purely a function of apoptotic versus nonapoptotic death in that the comparator whole cell vaccine also showed evidence of early apoptosis after irradiation. It may be possible that the differences in vaccine efficacy were due to immunological stimulation after specific caspase activation, 33 or may have been due to an innate response to viral gene products and/or alloantigens 34 or the metabolites of ganciclovir conversion known to accumulate. 35 In conclusion, ex vivo cell kill using HSVtK/ganciclovir in the rat prostate model results in the induction of apoptosis, and is immunogenic in the context of both autologous and allogeneic cancer vaccines. Further work is required in this and other models to define the precise humoral and cellular mechanisms underlying our observations, the role of innate immunity in this vaccine approach and the induction of antigen-specific responses.
